AstraZeneca may be eyeing a blockbuster deal to acquire Bristol Myers Squibb, merging two pharma titans valued at nearly $400 billion — but investors are puzzled. AstraZeneca’s stock dipped sharply as skeptics question the move, pointing to its strong R&D pipeline and innovation-driven CEO. Analysts warn past mega-mergers rarely deliver, and with AstraZeneca already thriving, the urgency of this acquisition remains unclear. The market is on edge, waiting to see if this bold strategy will pan out or fade into rumor.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/4cf80247cc1e2891

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av, eller tillsammans med, Poddtoppen.